Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic
Authors:
- Elizabeth FisherEFElizabeth Fisher
- Stephen E. JonesSJStephen E. Jones
- Claire Hara-CleaverCHClaire Hara-Cleaver
- Jar-Chi LeeJLJar-Chi Lee
- Richard A. RudickRRRichard A. Rudick
Open Access
- 1 March 2013
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 70 (3) , 338-344
Abstract
Magnetic resonance imaging (MRI) has a high sensitivity for focal white matter lesions that characterize multiple sclerosis (MS). Quiz Ref ID Magnetic resonance imaging lesion assessment has taken a central role in diagnosis,1,2 prognosis,3-5 and drug development.6,7 In fact, treatment effect on lesion activity has been used to screen all currently approved MS disease-modifying drugs. Treatment effect on MRI lesions parallels treatment effects on relapses and worsening disability, as measured by the Kurtzke Expanded Disability Status Scale.7-9Keywords
This publication has 28 references indexed in Scilit:
- Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple SclerosisPLOS ONE, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Surrogate endpoints for EDSS worsening in multiple sclerosisNeurology, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosisThe Lancet Neurology, 2009
- Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approachAnnals of Neurology, 2009
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009
- MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Rating neurologic impairment in multiple sclerosisNeurology, 1983